Investor Alert

New York Markets Open in:

press release

June 1, 2020, 5:01 p.m. EDT

Pharmacovigilance Market To Reach USD 12.98 Billion By 2027 | Reports and Data

The growing prevalence of adverse drug reaction and toxicity is one of the significant factors influencing the market growth.

New York, June 01, Jun 01, 2020 (GLOBE NEWSWIRE via COMTEX) -- New York, June 01, 2020 (GLOBE NEWSWIRE) -- The global pharmacovigilance market is expected to reach USD 12.98 Billion by 2027, according to a new report by Reports and Data. Every drug is associated with beneficial, as well as an undesirable or adverse effect. The major focus of pharmacovigilance is on adverse drug reactions (ADR), a common clinical problem, and drug toxicity. According to the studies conducted by the WHO (World Health Organization), in developed countries, nearly 5% of hospitalized patients are admitted into hospital as a result of an ADR, and 6-10% of in-patients are expected to experience a serious ADR during hospitalization. The pharmacovigilance market consists of all types of adverse events reporting conducted during clinical trials in hospitals, pharmacies, and other healthcare sectors. Increasing demand for acceptance and adoption of outsourcing services by healthcare companies will stimulate pharmacovigilance market growth during the forecast period. Moreover, Outsourcing eliminates the risk of business overhead costs as well as the deployment of pharmacovigilance resources.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/2253

Outsourcing strategy increases the cost-effectiveness and efficiency by relieving resource pressure on firms, thereby positively supporting the market growth. Positively shifting trends in PV outsourcing owing to increasing benefits will accelerate pharmacovigilance market growth in the coming years. Major pharmaceutical industry key players are significantly involved in extensive R&D initiatives for the development of innovative therapeutic molecules to bring out the best outcomes. This has successfully resulted in increased drug development activities over a period of time. Manufacturers are keenly focusing on remodeling their product development processes and work on the product portfolio and improvise the service provided by them in order to make an attempt to fulfill the unmet demand of patients across the globe. These factors are collectively anticipated to boost the pharmacovigilance market.

COVID-19 ImpactHealthcare organizations/agencies across the globe are evaluating the impact of the COVID-19 pandemic and providing new guidance on clinical trial management by sponsors and pharmacovigilance systems. This swiftly changing circumstances require sponsors to be more proactive and vigilant in ascertaining the effects of the pandemic and variations in authority expectations to decrease the impact on safety reporting while maintaining patient safety. At present, it has become essential to request revised instructions and implement regulatory changes rapidly to lessen interruptions to clinical trials. To deal with the present situation in an effective manner, it is necessary to have and recognized and strong safety reporting solution.

Further key findings from the report suggest

  • By type, spontaneous reporting contributed to the largest market share in 2019. The spontaneous reporting system is indispensable in pharmacovigilance by delivering information from actual clinical settings during the life of a drug. Physicians and various other healthcare experts may contribute vastly to enhancing public health by reporting suspected adverse drug reactions.

  • By service provider, the in-house service provider is likely to grow at a rate of 12.3% in the forecast period. Reporting to partners, Health Authorities: Most of the firms favor in-house handling of reporting to healthcare authorities and partners, possibly because they should be the principal contact entity for any deliberation, in and out.

  • By the clinical trial phase, phase IV contributed to the largest market share in 2019 and is expected to witness a growth rate of 13.1% in the forecast period. The increasing intricacy of therapeutic agents and biologics and a rise in the usage of new agents past the original purpose and testing, it is crucial to recognize at the earliest, any unwanted and unexpected Adverse Events and other severe toxicities. The well-known instances of drugs withdrawn from the market after being approved confirm the need for Phase IV pharmacovigilance.

  • By end-users, hospitals contributed to the largest market share in 2019 and is likely to grow at a rate of 13.2% in the forecast period. Hospital pharmacists are of utmost significance in ADR reporting, as the majority of the serious adverse drug events happen in hospitals, and ADRs are responsible for a considerable proportion of hospital admissions.

  • The market in the Asia Pacific region is estimated to grow at the fastest rate of 14.3% in the forecast period, owing to stringent regulatory norms for reporting ADRs, along with a large number of firms providing pharmacovigilance outsourcing services. Furthermore, growing funding for clinical trials is also causative of the market growth in the region.

  • Key participants include Accenture, Cognizant, ArisGlobal, IBM Corporation, IQVIA, BoClinica Inc., Laboratory Corporation of America Holdings, Linical Accelovance, Capgemini, and ITClinical, among others.

  • In April 2017, Accenture entered a collaborative agreement with BioCelebrate to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities.

BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/2253

For the purpose of this report, Reports and Data have segmented the global pharmacovigilance market on the basis of type, service provider, clinical trial phase, end-users, and region:

Type Outlook (Revenue, USD Million; 2017-2027)

  • Spontaneous Reporting

  • Intensified Adverse Drug Reaction (ADR) Reporting

  • Targeted Spontaneous Reporting

  • Cohort Event Monitoring

  • Electronic Health Record (HER) Mining

Service Provider Outlook (Revenue, USD Million; 2017-2027)

  • In-House

  • Contract Outsourcing

Clinical Trial Phase Outlook (Revenue, USD Million; 2017-2027)

  • Pre-Clinical

  • Phase I

  • Phase II

  • Phase III

  • Phase IV

End-Users Outlook (Revenue, USD Million; 2017-2027)

  • Hospitals

  • Research Organizations

  • Others

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/pharmacovigilance-market

Regional Outlook (Revenue, USD Million; 2017-2027)

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • MEA

Take a Look at our Related Reports:

E-Prescribing Market: https://www.reportsanddata.com/report-detail/e-prescribing-market

Mobile Health (mHealth) Market: https://www.reportsanddata.com/report-detail/mobile-health-mhealth-market

Artificial Intelligence in Drug Discovery Market: https://www.reportsanddata.com/report-detail/artificial-intelligence-in-drug-discovery-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

        Contact Us:
        John Watson
        Head of Business Development
        Reports And Data | Web: www.reportsanddata.com
        Direct Line: +1-212-710-1370
        E-mail: sales@reportsanddata.com

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2020 GlobeNewswire, Inc. All rights reserved.

Link to MarketWatch's Slice.